Resveratrol-Zinc Combination for Prostate Cancer

白藜芦醇-锌组合治疗前列腺癌

基本信息

  • 批准号:
    8519846
  • 负责人:
  • 金额:
    $ 19.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Novel mechanism-based approaches are needed for prostate cancer (PCa) management. A number of studies have suggested an important role of Zinc (Zn) in prostate biology. Zn exists in very high concentrations in the healthy prostate and is important for prostatic functions. Interestingly, in the cancerous prostatic tissue, the Zn level i significantly diminished and intracellular Zn levels have a strong inverse correlation with PCa progression. Therefore, Zn seems to play a critical role in PCa progression. During neoplastic transformation the normal prostate epithelial cells that are Zn-accumulating citrate producing cells seem to be metabolically transformed to citrate-oxidizing cells that lose the ability to accumulate Zn. Further, studies have suggested that a diminished expression of Zn transporter proteins (ZIPs), especially ZIP1, ZIP2 and ZIP3 may be associated with this metabolic transformation. Thus, apparently, down regulation of ZIPs in PCa tissue leads to low bioaccumulation of Zn. Interestingly, ZIP1 down-regulation in PCa was found to involve the overexpression of Ras responsive element binding protein-1 (RREB1). Restoration of adequate Zn levels in PCa cells has been shown to inhibit malignant potential. Further, Zn has been shown as a chemopreventive agent against PCa and supplementation with high dose of Zn may be useful. However, high dose of Zn is associated with many adverse effects. Further, malignant prostate cells in situ are incapable of accumulating high Zn levels from circulation. Therefore, novel means to enhance the bioaccumulation of sufficient Zn in the prostate cells via increasing ZIP-mediated Zn transport could be useful towards PCa management. Resveratrol, an antioxidant found in grapes and red wines, is shown to be capable of affording chemopreventive as well as therapeutic effects against PCa. A recent study has shown that resveratrol in combination with Zn dramatically increases the cellular Zn concentration in normal human prostate epithelial cells. Our preliminary data suggests that 1) a combination of resveratrol with Zn imparts a better anti-proliferative response in PCa cells, and 2) resveratrol-Zn increases ZIP proteins (ZIP1, ZIP2 and ZIP3) levels in PCa cells. Thus, based on published studies and our preliminary data, the hypothesis to be tested in this application is that resveratrol when combined with zinc will enhance its bioaccumulation, via RREB1 inhibition mediated increase in zinc-transporters (ZIP1, ZIP2 and ZIP3) in prostate, to impart a significantly superior chemopreventive and therapeutic response against PCa. Two specific aims are proposed: 1) To determine if a combination of resveratrol and Zn imparts superior chemopreventive and/or therapeutic response against PCa in vivo; 2) To determine the mechanism(s) of resveratrol-Zn combinatorial action. Outcome of our pilot study may provide useful information regarding the effectiveness of resveratrol-Zn combinatorial approach in PCa management, enabling us to design future in-depth studies including PCa clinical trial in human population.
描述(由申请人提供):前列腺癌(PCa)管理需要新的基于机制的方法。许多研究表明,锌(Zn)在前列腺生物学中起着重要作用。锌在健康前列腺中以非常高的浓度存在, 对前列腺功能很重要。有趣的是,在癌性前列腺组织中,Zn水平显著降低,并且细胞内Zn水平与PCa进展具有强的负相关性。因此,Zn似乎在PCa进展中起关键作用。在肿瘤转化过程中,正常的前列腺上皮细胞,即锌积累柠檬酸盐生产细胞,似乎代谢转化为柠檬酸盐氧化细胞,失去了积累锌的能力。此外,研究表明,锌转运蛋白(ZIPs),特别是ZIP 1,ZIP 2和ZIP 3的表达减少可能与这种代谢转化有关。因此,显然,PCa组织中ZIPs的下调导致Zn的低生物累积。有趣的是,发现PCa中ZIP 1的下调涉及Ras反应元件结合蛋白-1(RREB 1)的过表达。已显示PCa细胞中足够的Zn水平的恢复抑制恶性潜能。此外,锌已被证明是针对PCa的化学预防剂,并且补充高剂量的锌可能是有用的。然而,高剂量的锌与许多不良反应有关。此外,原位的恶性前列腺细胞不能从循环中积累高水平的Zn。因此,通过增加ZIP介导的Zn转运来增强足够的Zn在前列腺细胞中的生物累积的新方法可能对PCa管理有用。白藜芦醇是一种在葡萄和红葡萄酒中发现的抗氧化剂,被证明能够提供对PCa的化学预防和治疗作用。最近的一项研究表明,白藜芦醇与锌的组合显着增加正常人前列腺上皮细胞中的细胞锌浓度。我们的初步数据表明,1)白藜芦醇与锌的组合赋予PCa细胞更好的抗增殖反应,2)白藜芦醇-锌增加PCa细胞中的ZIP蛋白(ZIP 1,ZIP 2和ZIP 3)水平。因此,基于已发表的研究和我们的初步数据,在本申请中待检验的假设是白藜芦醇当与锌组合时将通过RREB 1抑制介导的前列腺中锌转运蛋白(ZIP 1、ZIP 2和ZIP 3)的增加来增强其生物累积,从而赋予针对PCa的显著上级化学预防和治疗应答。提出了两个具体目的:1)确定白藜芦醇和Zn的组合是否在体内赋予针对PCa的上级化学预防和/或治疗反应; 2)确定白藜芦醇-Zn组合作用的机制。我们的初步研究的结果可能提供有用的信息,白藜芦醇锌组合方法在PCa管理的有效性,使我们能够设计未来的深入研究,包括PCa在人群中的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nihal Ahmad其他文献

Nihal Ahmad的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nihal Ahmad', 18)}}的其他基金

Combined inhibition of PLK1 and NOTCH for melanoma management
联合抑制 PLK1 和 NOTCH 治疗黑色素瘤
  • 批准号:
    10481129
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10481027
  • 财政年份:
    2022
  • 资助金额:
    $ 19.64万
  • 项目类别:
Functional and Therapeutic Significance of PLK4 in Melanoma
PLK4 在黑色素瘤中的功能和治疗意义
  • 批准号:
    10442947
  • 财政年份:
    2022
  • 资助金额:
    $ 19.64万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10593106
  • 财政年份:
    2022
  • 资助金额:
    $ 19.64万
  • 项目类别:
Functional and Therapeutic Significance of PLK4 in Melanoma
PLK4 在黑色素瘤中的功能和治疗意义
  • 批准号:
    10671687
  • 财政年份:
    2022
  • 资助金额:
    $ 19.64万
  • 项目类别:
Role of sirtuin 6 in melanoma development and progression
Sirtuin 6 在黑色素瘤发生和进展中的作用
  • 批准号:
    10426079
  • 财政年份:
    2021
  • 资助金额:
    $ 19.64万
  • 项目类别:
Role of sirtuin 6 in melanoma development and progression
Sirtuin 6 在黑色素瘤发生和进展中的作用
  • 批准号:
    10595641
  • 财政年份:
    2021
  • 资助金额:
    $ 19.64万
  • 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
  • 批准号:
    10046297
  • 财政年份:
    2018
  • 资助金额:
    $ 19.64万
  • 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
  • 批准号:
    9551225
  • 财政年份:
    2018
  • 资助金额:
    $ 19.64万
  • 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
  • 批准号:
    10421255
  • 财政年份:
    2018
  • 资助金额:
    $ 19.64万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了